Biotinyl-GHK: A Miracle Ingredient Against Hair Loss?

The search for effective solutions to combat hair loss has led to the research of various bioactive compounds. Among them, biotinyl-GHK has emerged as a marketed ingredient in hair treatments. This article looks at what biotinyl-GHK is, its proposed mechanism of action, and what the published evidence does and does not show about its use in alopecia.

What is Biotinyl-GHK?

Biotinyl-GHK is a bioactive peptide built from three amino acids — glycine, histidine, and lysine — with a biotin molecule attached. In cosmetic ingredient lists it usually appears as biotinoyl tripeptide-1. The idea behind it is to combine the regenerative properties attributed to the tripeptide GHK with the structural role of biotin. It is a cosmetic ingredient, not an approved medicine for hair loss.

Each component is worth taking separately.

Tripeptide GHK (Glycine-Histidine-Lysine)

GHK is a peptide found naturally in the human body that has been studied for its role in tissue repair, wound healing, and cell regeneration. Most of that research concerns GHK-Cu, the copper-bound form, which is not the same molecule as biotinyl-GHK.

In the context of hair growth, laboratory work reports that GHK-Cu helps cells within hair follicles multiply more quickly, reduces programmed cell death (apoptosis) in the follicles, and reduces inflammation and oxidative damage in the surrounding tissue — all of which, in principle, would create more favourable conditions for hair growth.

The published research does support several of these properties, with important caveats. Reviews report that this peptide promotes skin remodeling, wound healing, and regeneration, and shows antioxidant and anti-inflammatory effects in in vitro and in vivo studies. Those findings are the basis for the interest in GHK-Cu, but they are not the same as evidence that it treats hair loss in people.

The caveats matter. First, most research has been conducted in vitro or in animal models, which does not always predict the same result in humans. Large-scale, long-term clinical trials confirming effectiveness and safety across different patient groups are lacking. There is also no consensus on an ideal dose or route of administration, as it has been studied mainly in topical applications. There is a theoretical concern about copper as well: GHK-Cu transports copper, and an excess of that metal in the body can induce oxidative stress.

Another point is the lack of regulation and standardization in the production of GHK-Cu, which means product quality varies across the market. Some studies have been funded by companies that sell peptides, which is worth knowing when reading their conclusions. Finally, although laboratory studies suggest GHK-Cu can promote hair growth, there is not enough evidence to claim it is more effective than standard treatments such as minoxidil or finasteride, because no clinical trial has compared them directly.

Biotin

Biotin, also known as vitamin B7 or vitamin H, is an essential nutrient involved in the metabolism of carbohydrates, fats and proteins. It is found naturally in foods such as eggs, nuts and legumes. Its link to hair health comes from its role in producing keratin, a key protein in the structure of hair, skin and nails. Biotin deficiency can cause hair weakening and brittle nails, but reviews note that deficiency is rare in people eating a balanced diet.

Marketing around biotin products is often misleading, suggesting any hair problem can be solved by taking this vitamin, when hair loss has many causes. Alopecia can stem from genetics (as in androgenetic alopecia), hormonal problems, stress, autoimmune disease or the side effects of medication. Hair can also be weakened by deficiencies in other nutrients such as iron, zinc, vitamin D or protein.

Interest in peptides

Companies are interested in commercializing peptides because demand is growing in the cosmetic and dermatological industry. According to a report by Mordor Intelligence, the cosmetic peptide synthesis market was projected to grow at a compound annual rate of 5.5% through 2028. Peptides are marketed for their reported ability to stimulate collagen production, improve skin barrier function, reduce inflammation, and address pigmentation.

There is a regulatory dimension too. Unlike drugs such as finasteride or minoxidil, which need regulatory approval for hair-loss claims, many peptides are sold as cosmetic ingredients or supplements under less stringent rules. That lets companies bring products to market faster and at lower compliance cost — and it also means the evidence bar those products clear is much lower.

Collagen: the common point of biotin and GHK tripeptide

Collagen is one of the most abundant proteins in the human body and plays a role in the health of skin, connective tissue and hair. Both biotin and the GHK tripeptide are connected to collagen, which is the rationale manufacturers give for combining them.

Biotin contributes to the synthesis of keratin, a structural protein of hair, skin and nails; its deficiency can cause hair fragility and weakened hair fibres. It does not act directly on collagen production, though it participates in the metabolism of fatty acids and amino acids involved in it.

The tripeptide GHK, for its part, has been shown in cell and animal studies to stimulate collagen synthesis in skin and connective tissue, and to promote wound healing and cell repair. Manufacturers describe the combination in biotinyl-GHK as enhancing that effect at the hair follicle; that synergy is a product rationale, not something a published human study has demonstrated.

Biotinyl-GHK and studies

Biotinyl-GHK is rarely studied on its own. In practice it is one component of the cosmetic complex marketed as Procapil, alongside apigenin and oleanolic acid, and the published trials test the complex — usually combined with other actives again — rather than the peptide by itself. That is the central limitation of the evidence base.

Pavithra and colleagues (2023, Cureus) compared topical Procapil plus platelet-rich plasma against topical Redensyl, saw palmetto and biotin plus platelet-rich plasma in androgenetic alopecia. Samadi and colleagues (2023, Journal of Cosmetic Dermatology) assessed a topical formulation containing caffeine and 3% Procapil in male pattern hair loss. Karaca and Akpolat (2019) compared a Redensyl, Capixyl and Procapil combination against topical 5% minoxidil over 24 weeks. In each case the tested product contained several active ingredients, so no result can be attributed to biotinyl-GHK alone, and none of these were large trials.

Biotinyl-GHK is also reported in supplier and laboratory literature to stimulate production of collagen type IV and laminin 5 in dermal and epidermal cells, which is proposed to strengthen the anchorage of the hair follicle. This remains a laboratory finding and a manufacturer's rationale rather than a demonstrated clinical outcome.

Research on biotinyl-GHK is limited, and larger clinical studies are needed to establish what it does and how safe it is across different populations. As always, it is advisable to consult with a healthcare professional or pharmacist before starting any hair loss treatment, especially before combining a cosmetic product with a prescribed one. As for the community, users report improvements in hair density and less shedding after consistent use of products containing biotinyl-GHK; those reports come from multi-ingredient formulations, and individual responses vary.

Sources

Pickart, L., & Margolina, A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987

Pavithra, T. R., Rajashekar, T. S., Suresh Kumar, K., & Harish Prasanna. (2023). A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia. Cureus, 15(5), e38696. https://doi.org/10.7759/cureus.38696

Samadi, A., Rokhsat, E., Saffarian, Z., & Goudarzi, N. (2023). Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss. Journal of Cosmetic Dermatology, 23, 1492–1494. https://doi.org/10.1111/jocd.16102

Karaca, N., & Akpolat, N. D. (2019). A Comparative Study between Topical 5% Minoxidil and Topical "Redensyl, Capixyl, and Procapil" Combination in Men with Androgenetic Alopecia. Journal of Cosmetology & Trichology, 5(1).

Siah, T. W., & Muir, J. (2023). Combining topical minoxidil with Procapil: an assessment of their efficacy in the treatment of androgenetic alopecia. Journal of Pakistan Association of Dermatologists, 33(4), 654–659. https://www.jpad.com.pk/index.php/jpad/article/view/2541

Hafeez, F., & Ahmed, I. (2017). Efficacy and Safety of a New Topical Hair Loss-Lotion Containing Oleanolic Acid, Apigenin, Biotinyl Tripeptide-1, Diaminopyrimidine Oxide, and Panthenol in Healthy Male and Female Volunteers. Journal of Clinical and Experimental Dermatology Research, 8(2), 1000132.

John, A. M., Schwartz, R. A., & Janniger, C. K. (2021). Biotin for Hair Loss: Teasing Out the Evidence. Journal of Clinical and Aesthetic Dermatology, 14(1), 55–59. https://jcadonline.com/biotin-for-hair-loss-evidence/

Maquart, F. X., Bellon, G., Chaqour, B., Wegrowski, Y., Patt, L. M., Trachy, R. E., & Pickart, L. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 92(5), 2368–2376. https://doi.org/10.1172/JCI116830

Canapp, S. O., Farese, J. P., Schultz, G. S., Gowda, S., Ishak, A. M., Swaim, S. F., et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 32(6), 515–523. https://doi.org/10.1053/jvet.2003.50072

Gul, N. Y., Topal, A., Cangul, I. T., & Yanik, K. (2008). The effects of topical tripeptide copper complex and helium-neon laser on wound healing in rabbits. Veterinary Dermatology, 19(1), 8–14. https://doi.org/10.1111/j.1365-3164.2008.00650.x

Conato, C., Gavioli, R., Guerrini, R., Kozłowski, H., & Młynarz, P. (2000). Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: Chemical behaviour and biological activity. Biochimica et Biophysica Acta (BBA) - General Subjects, 1475(1), 47–53. https://doi.org/10.1016/S0304-4165(00)00098-0

Hureau, C., Eury, H., Guillot, R., Bijani, C., Sayen, S., & Faller, P. (2011). X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: Influence on their redox properties. Chemistry — A European Journal, 17(35), 10151–10160. https://doi.org/10.1002/chem.201100654

Lau, S. J., & Sarkar, B. (1971). The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochemical Journal, 124(4), 751–757. https://doi.org/10.1042/bj1240751

Gorouhi, F., & Maibach, H. I. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 31(5), 327–345. https://doi.org/10.1111/j.1468-2494.2009.00523.x

Pickart, L., & Thaler, M. M. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology, 243(124), 85–87. https://doi.org/10.1038/newbio243085a0

Schlesinger, D. H., & Hay, D. I. (1977). Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Cellular and Molecular Life Sciences, 33(3), 317–318. https://doi.org/10.1007/BF01945327

Maquart, F. X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J. C., & Borel, J. P. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 238(2), 343–346. https://doi.org/10.1016/0014-5793(88)80210-3

Wegrowski, Y., Maquart, F. X., & Borel, J. P. (1992). Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sciences, 51(13), 1049–1056. https://doi.org/10.1016/0024-3205(92)90505-2

Siméon, A., Emonard, H., Hornebeck, W., & Maquart, F. X. (2000). The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences, 67(18), 2257–2265. https://doi.org/10.1016/S0024-3205(00)00820-0